SecBot SecBot
Insider Cluster (2 insiders) ·Filed Mar 31, 2026

CYTK

CYTOKINETICS INC
BEARISH
Impact 6/10
Horizondays Processed7mo ago
Insider cluster: 2 insiders, $736K total
Actionable Insight ▼ Bearish

Monitor for additional insider selling or downward revisions in guidance; CEO and top commercial executive selling simultaneously may signal caution ahead of key catalysts or clinical readouts.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$66.61
T+0 close · Mar 31, 2026 · via day close
Latest settled
+31.00%
T+60 · $87.26
Vs SPY
+17.91%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 1 $66.61entry
  2. T+1 · 8mo ago +0.18%α +0.09% · $66.73
  3. T+5 · 7mo ago −3.03%α −6.80% · $64.59
  4. T+20 · 7mo ago −3.96%α −13.64% · $63.97
  5. T+60 · 5mo ago +31.00%α +17.91% · $87.26
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two top executives at Cytokinetics, including CEO Robert Blum, sold shares in a coordinated 7-day window, generating $736,000 in total proceeds. The sales represent a modest but notable insider selling cluster, with both executives liquidating holdings at market prices.

Key Financial Metrics

Direction
selling
Total Value
$736.3K
Insiders
2

Key Facts

  • CEO Robert Blum sold 7,500 shares for $499,725 in open-market transaction on April 1, 2026.
  • EVP Andrew Callos sold 3,639 shares for $236,535 on March 31, 2026.
  • Total cluster value: $736,260 in open-market sales by C-suite executives.
  • Sales represent 0.009% of Cytokinetics' $8.1B market cap, modest in scale but concerning due to executive rank.

Financial Impact

$736K in insider sales over 7 days

insider ownershipinvestor sentiment

Risk Factors

  • Perception of insider lack of confidence, especially from CEO during critical development phase
  • Potential for negative market reaction if no offsetting positive news follows

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-CYTK-1775075710713

Track record

46 reports on CYTK

Performance horizon

6 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
  2. Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $53.17 −5.27% settles Dec 14
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
  4. Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
  5. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
  6. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
  7. Nov 4, 202612d ago 8-K Bullish 6/10 No price data
  8. Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $53.17 −4.28% settles Dec 4
  9. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
  10. Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $53.17 −14.28% settles Dec 1
Showing 10 of 46

US Market Status

Market Closed · Opens Wed (11h 46m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 1, 2026